| Literature DB >> 31589980 |
Hye Won Lee1, Jun Yong Park1, Taegon Hong2, Min Soo Park3, Sang Hoon Ahn4.
Abstract
The mechanism of action of hepatitis B immunoglobulin (HBIG) for chronic hepatitis B (CHB) treatment is not fully understood. A clinical trial in Japan suggested that HBIG therapy might benefit patients with CHB.1 Lenvervimab, a recombinant monoclonal HBIG developed by GC Pharma (Yongin, South Korea), has been screened from an anti-HBs-enriched phage-display library cloned from hepatitis B vaccine-boosted human blood cells and was produced in Chinese hamster ovary cells.2-4.Entities:
Year: 2019 PMID: 31589980 DOI: 10.1016/j.cgh.2019.09.038
Source DB: PubMed Journal: Clin Gastroenterol Hepatol ISSN: 1542-3565 Impact factor: 11.382